低リスクの乳頭状甲状腺がんの初治療における論争
Donald S A McLeod1, Anna M Sawka, David S Cooper
1Department of Internal Medicine and Aged Care, Royal Brisbane and Women's Hospital, Herston, QLD, Australia.
Lancet (London, England)
|May 15, 2013
まとめ
パピラー性甲状腺がんの発生率は,世界的に上昇しています. このレビューでは,流行病学的データと管理ガイドラインを検証し,この一般的な悪性腫瘍に対する治療的枠組みを提供しています.
科学分野:
- 腫瘍学 腫瘍学
- エピデミオロジー エピデミオロジー
- エンドクリノロジー エンドクリノロジー
背景:
- パピラー性甲状腺がんの発生率は世界中で急速に増加しており,重大な臨床的課題となっています.
- 診断された多くの症例は小さく,リスクが低いものの,効果的な管理戦略については依然として議論されている.
- 特に低リスクの疾患では,従来のトリアード治療の効果を明確に証明するのは困難です.
研究 の 目的:
- パピラー甲状腺がんの発生率に関する現在の疫学データをレビューする.
- 乳頭状甲状腺がんの管理における論争について議論する.
- 入手可能な証拠と臨床ガイドラインに基づいて治療の枠組みを提案する.
主な方法:
- パピラー甲状腺がんの発生率に関する疫学データの体系的なレビュー.
- 既存の臨床実務ガイドラインの分析と管理戦略のための証拠.
- 治療の枠組みを作成するための情報の合成.
主要な成果:
- パピラー性甲状腺がんは,世界中で最も急速に増加している悪性腫瘍です.
- 伝統的な治療トリアード (外科手術,放射性ヨウ素,TSH抑制) を支持する証拠は,特に低リスク疾患については限られています.
- 臨床実務ガイドラインは存在するが,ランダム化対照試験の欠如によって妨げられている.
結論:
- 乳毛性甲状腺がんの流行病学の明確な理解は,効果的な管理に不可欠です.
- リスクの階層化と,個別化された治療アプローチは不可欠です.
- 管理ガイドラインを洗練し,患者のアウトカムを最適化するために,ランダム化比較試験を含むさらなる研究が必要です.
関連する概念動画
Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Hyperthyroidism I: Introduction
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Hypothyroidism II: Pathophysiology
Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
